Stay updated on ALT-803 Plus Nivolumab in Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the ALT-803 Plus Nivolumab in Lung Cancer Clinical Trial page.

Latest updates to the ALT-803 Plus Nivolumab in Lung Cancer Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe web page has been updated from version v2.16.1 to v2.16.2.SummaryDifference0.1%
- Check21 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference1%
- Check28 days agoNo Change Detected
- Check50 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check64 days agoChange DetectedThe page has undergone significant content changes, including the removal of detailed study information regarding a Phase IB/II study of Nivolumab in combination with ALT-803 for Non-Small Cell Lung Cancer, while retaining the mention of collaborators and the revision number.SummaryDifference29%
- Check71 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check78 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
Stay in the know with updates to ALT-803 Plus Nivolumab in Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ALT-803 Plus Nivolumab in Lung Cancer Clinical Trial page.